Trial reportThe Journal of allergy and clinical immunology2024
Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial.
Trial report in The Journal of allergy and clinical immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Biologic-assisted immunotherapy for pediatric food allergy: a systematic review.Frontiers in allergy · 2026Pooled it
- Guideline
- Epithelial immunotherapy for food allergy in children: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Dosing Reactions and Missed Doses Affect Peanut Oral Immunotherapy Outcomes.The journal of allergy and clinical immunology. In practice · 2026Trial
- Baseline basophil activation and early suppression is associated with clinical outcome after peanut sublingual immunotherapy.The Journal of allergy and clinical immunology · 2025Trial
- Active Paediatric Food-Allergy Interventions Pursue Distinct Clinical Goals: A Brief, Goal-Directed Synthesis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Article
- Article
- Pragmatic Strategies for Reducing Variability and Risk in Food Oral Immunotherapy.Clinical reviews in allergy & immunology · 2026Review
- Clinical remission in allergy and clinical immunology practice: State of the art and World Allergy Organization (WAO) call to action.The World Allergy Organization journal · 2026Review
- Efficacy and safety of Sublingual immunotherapy for allergic rhinitis: an overview of systematic reviews and meta analyses.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Review
- Review
- Wheat allergy, a new and emerging threat of food allergy for children.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Review
- Sublingual Immunotherapy for Food Allergy: Updates in Safety, Efficacy, and Future Considerations.Current allergy and asthma reports · 2026Review
- Eating away at food allergy.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025Review
- Observational
- Immunotherapy in Peanut Allergy: The Present and the Future.Allergy, asthma & immunology research · 2025Article
- Epicutaneous immunotherapy for food allergy: A systematic review and meta-analysis.Clinical and translational allergy · 2025Review
- Food oral immunotherapy.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025Review
- Roads to remission: evolving treatment concepts in type 2 inflammatory diseases.EClinicalMedicine · 2025Review
- Scientific developments in understanding food allergy prevention, diagnosis, and treatment.Frontiers in immunology · 2025Review
Corrections and comments
- Commented on by
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPrior studies of peanut sublingual immunotherapy (SLIT) have suggested a potential advantage with younger age at treatment initiation.
objectiveWe studied the safety and efficacy of SLIT for peanut allergy in 1- to 4-year-old children.
methodsPeanut-allergic 1- to 4-year-old children were randomized to receive 4 mg peanut SLIT versus placebo. Desensitization was assessed by double-blind, placebo-controlled food challenge (DBPCFC) after 36 months of treatment. Participants desensitized to at least 443 mg peanut protein discontinued therapy for 3 months and then underwent DBPCFC to assess for remission. Biomarkers were measured at baseline and longitudinally during treatment.
resultsFifty participants (25 peanut SLIT, 25 placebo) with a median age of 2.4 years were enrolled across 2 sites. The primary end point of desensitization was met with actively treated versus placebo participants having a significantly greater median cumulative tolerated dose (4443 mg vs 143 mg), higher likelihood of passing the month 36 DBPCFC (60% vs 0), and higher likelihood of demonstrating remission (48% vs 0). The highest rate of desensitization and remission was seen in 1- to 2-year-olds, followed by 2- to 3-year-olds and 3- to 4-year-olds. Longitudinal changes in peanut skin prick testing, peanut-specific IgG
conclusionPeanut SLIT safely induces desensitization and remission in 1- to 4-year-old children, with improved outcomes seen with younger age at initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.